Neurological disorders are becoming a growing burden as society ages, and there is a
compelling need to address this spiraling problem. Stem cell‐based regenerative medicine …

Due to their robust immunomodulatory capabilities, mesenchymal stem/stromal cells (MSCs)
have been used as a cellular therapy for a number of human diseases. Part of the …

Objective To explore the role of alpha‐synuclein (αSyn) oligomers and neurofilament light
chain (NFL) in cerebrospinal fluid (CSF) as markers of early multiple system atrophy (MSA) …

Mesenchymal stem/stromal cells (MSCs) have been carefully examined to have tremendous
potential in regenerative medicine. With their immunomodulatory and regenerative …

Multiple system atrophy (MSA) is a rare and fatal neurodegenerative disorder characterized
by a variable combination of parkinsonism, cerebellar impairment, and autonomic …

Chronic liver diseases have become a significant health issue worldwide and urgently
require the development of novel therapeutic approaches, in addition to liver transplantation …

Background: Autologous mesenchymal stem cell neurotrophic factor–secreting cells
(NurOwn®) have the potential to modify underlying disease mechanisms in progressive …

The Unified Multiple System Atrophy Rating Scale (UMSARS) was developed almost two
decades ago as a clinical rating scale to capture multiple aspects of the disease. 1, 2 It is …

Multiple system atrophy (MSA) is a sporadic, adult-onset, relentlessly progressive
neurodegenerative disorder, clinically characterized by various combinations of autonomic …

Multiple system atrophy (MSA) is a debilitating and fatal neurodegenerative disorder. The
disease severity warrants urgent development of disease-modifying therapy, but the disease …